Literature DB >> 7389258

Colchicine kinetics in patients with familial Mediterranean fever.

H Halkin, S Dany, M Greenwald, Y Shnaps, M Tirosh.   

Abstract

Serum colchicine levels were determined by radioimmunoassay after a 1-mg bolus injected intravenously in 4 patients with familial Mediterranean fever and in 6 normal subjects. Mean elimination half-life (t1/2) (+/- SEM) was 157 +/- 20 min in the patients and 65 +/- 15 min in the normal subjects (p less than 0.005). Total clearance was 239 +/- 50 ml/min in the patients and 601 +/- 155 ml/min in the normal subjects (p less than 0.05). Volume of distribution (Vdarea) was 76 +/- 16 and 49 +/- 91 and did not differ significantly. In 8 patients receiving colchicine prophylactically with good clinical response, serum colchicine ranged from 0.3 to 2.4 ng/ml after daily doses of 1 mg orally. In 2 responding patients 2-mg doses orally induced levels from 4 to 10 ng/ml, and in one (a nonresponder) a 3-mg dose induced levels of 7.5 to 13 ng/ml. Of 3 patients receiving 2 mg daily with unsatisfactory clinical responses, serum levels were not detectable in one and in the low range of 1.5 to 5.4 ng/ml in the others. It is suggested that lack of response to colchicine orally in some nonresponders could result from inadequate absorption or altered disposition of colchicine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389258     DOI: 10.1038/clpt.1980.135

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Pharmacokinetics/bioavailability of colchicine in healthy male volunteers.

Authors:  G Achtert; J M Scherrmann; M O Christen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

2.  Zero-order absorption and linear disposition of oral colchicine in healthy volunteers.

Authors:  G Thomas; C Girre; J M Scherrmann; P Francheteau; J L Steimer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

Authors:  Hakan Emmungil; Ufuk İlgen; Sezin Turan; Samet Yaman; Orhan Küçükşahin
Journal:  Rheumatol Int       Date:  2019-08-28       Impact factor: 2.631

4.  Effect of in vitro colchicine and oral theophylline on suppressor cell function of asthmatic patients.

Authors:  D Ilfeld; S Kivity; E Feierman; M Topilsky; O Kuperman
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

5.  Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicine-specific monoclonal antibody.

Authors:  S K Rouan; I G Otterness; A C Cunningham; H E Holden; C T Rhodes
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

6.  Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.

Authors:  M Rochdi; A Sabouraud; C Girre; R Venet; J M Scherrmann
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine.

Authors:  D Ilfeld; E Theodor; G Delpre; O Kuperman
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  Colchicine concentration in leukocytes of patients with familial Mediterranean fever.

Authors:  O Chappey; E Niel; M Dervichian; J L Wautier; J M Scherrmann; D Cattan
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

9.  Case report: fatal poisoning with Colchicum autumnale.

Authors:  Miran Brvar; Tom Ploj; Gordana Kozelj; Martin Mozina; Marko Noc; Matjaz Bunc
Journal:  Crit Care       Date:  2004-01-02       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.